MARVELD1 CRISPR/Cas9 KO Plasmid (h): sc-413502
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MARVELD1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MARVELD1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MARVELD1 CRISPR/Cas9 KO Plasmid (h) | sc-413502 | 20 µg | $397.00 |
Overview
MARVELD1 (MARVEL domain containing 1) encodes a small membrane-associated protein containing a MAL and related proteins for vesicle trafficking and membrane link (MARVEL) domain, consistent with roles in organizing membrane microdomains and regulating transmembrane protein dynamics. Reported functions link MARVELD1 to control of cell adhesion, proliferation, and differentiation programs, with downstream effects on cell-cycle checkpoints and stress-responsive signaling. Altered MARVELD1 expression has been observed across multiple tumor contexts and is frequently studied for its association with invasion, metastasis-related phenotypes, and transcriptional regulation networks. As a result, MARVELD1 serves as a useful node for investigating how membrane organization interfaces with signaling pathways that influence cellular plasticity and oncogenic traits.
MARVELD1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MARVELD1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MARVELD1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MARVELD1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MARVELD1 protein expression.
This CRISPR knockout system enables efficient generation of MARVELD1-deficient cell models for investigation of MARVELD1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MARVELD1 exon(s) critical for MARVELD1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MARVELD1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MARVELD1 CRISPR/Cas9 KO Plasmid (h) and MARVELD1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MARVELD1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MARVELD1 HDR Plasmid (h) and MARVELD1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MARVELD1 homology arms to support homology-directed repair at defined MARVELD1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.